Valerio Therapeutics SA
SWB:C4X

Watchlist Manager
Valerio Therapeutics SA Logo
Valerio Therapeutics SA
SWB:C4X
Watchlist
Price: 0.054 EUR Market Closed
Market Cap: 27.8m EUR

Gross Margin
Valerio Therapeutics SA

59.3%
Current
71%
Average
63.1%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
59.3%
=
Gross Profit
1.1m
/
Revenue
1.8m

Gross Margin Across Competitors

No Stocks Found

Valerio Therapeutics SA
Glance View

Market Cap
27.8m EUR
Industry
Biotechnology

Valerio Therapeutics SA is a is a clinical-stage biotechnology company, which engages in the development of drugs for the treatment of orphan diseases. The company is headquartered in Paris, Ile-De-France and currently employs 25 full-time employees. The company went IPO on 2005-07-12. The firm targets tumor DNA functions through unparalleled mechanisms of action in the sought-after field of DNA damage response (DDR). The company aims at holding a portfolio of advanced programs targeting severe pathologies with unmet clinical needs. The company has two programs in clinical development stage: Livatag, a doxorubicin Transdrag in Phase III, for the treatment of primary liver cancer, and Validive, a clonidine Lauriad in Phase II, for treatment of radio/chemo-induced severe oral mucositis at patients with head and neck cancer. The company also has one registered product in the United States, Beleodaq/ belinostat, for the treatment of peripheral T-Cell lymphoma (PTCL) and opportunities for further development; and two initial drugs registered in Europe and the United States: Loramyc/ Oravig for the treatment of oropharyngeal candidiasis, and Sitavig for the treatment of recurring herpes labialis.

C4X Intrinsic Value
0.032 EUR
Overvaluation 41%
Intrinsic Value
Price
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
59.3%
=
Gross Profit
1.1m
/
Revenue
1.8m
What is the Gross Margin of Valerio Therapeutics SA?

Based on Valerio Therapeutics SA's most recent financial statements, the company has Gross Margin of 59.3%.

Back to Top